Journal article · 2020 · Open access

FDA Reported Use of Patient Experience Data in 2018 Drug Approvals

Cameron M. Kieffer, Alexis Reisin Miller, Benjamin Chacko, Andrew S Robertson

Therapeutic Innovation & Regulatory Science, 54(3), 709–716 · Published 6 January 2020 · DOI 10.1007/s43441-019-00106-1

Open PDFView at the publisherCite this paper

In brief

“FDA Reported Use of Patient Experience Data in 2018 Drug Approvals” is a 2020 journal article by Cameron M. Kieffer and 3 co-authors, published in Therapeutic Innovation & Regulatory Science. OpenAlex counts 34 citations as of 22 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at Therapeutic Innovation & Regulatory Science.

Citations
34
Most cited in
2024 (9)
Field-weighted impact
4.35
References
1
Authors
4

Abstract

BACKGROUND: "Patient experience data" (PED) refers to the systematic collection of meaningful data relating to the experiences, perspectives, needs, and priorities of patients. PED can augment traditional clinical trial data in the FDA's review of product applications. Section 3001 of the 2016 21st Century Cures Act requires the FDA to make a public statement about the PED considered in the approval of a drug application. Here, we present one of the first assessments of PED consideration during drug application approval, as reported by the FDA under Sec. 3001 of the Cures Act. METHODS: FDA reported use of PED in the Review Documentation of the 59 new molecular entities (NMEs) approved in 2018 were collected, indexed, and cross-referenced against information regarding FDA review and product regulatory designation. The data reported in the PED tables were quantitatively described and visualized. RESULTS: Of the 59 approved NMEs in 2018, 48 include a table that summarized whether PED was or was not used during the FDA drug review. Thirty-four of those 48 approvals (70.8%) reported using PED in the drug review. Patient-reported outcomes(PROs) represented the most significant source of PED and were used in 60.4% of approved drug reviews. Additional findings, including PED use by FDA review division and by FDA regulatory designation, are described. CONCLUSIONS: This assessment is a first step to better understanding how FDA considers PED in regulatory decision making. This analysis should help develop a baseline regarding FDA use of PED and may inform decisions to ensure patients' experiences are adequately heard in future drug development.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Kieffer, C. M., Miller, A. R., Chacko, B., & Robertson, A. S. (2020). FDA Reported Use of Patient Experience Data in 2018 Drug Approvals. Therapeutic Innovation & Regulatory Science, 54(3), 709–716. https://doi.org/10.1007/s43441-019-00106-1

MLA 9

Kieffer, Cameron M., et al. “FDA Reported Use of Patient Experience Data in 2018 Drug Approvals.” Therapeutic Innovation & Regulatory Science, vol. 54, no. 3, 2020, pp. 709–716. https://doi.org/10.1007/s43441-019-00106-1.

Chicago

Kieffer, Cameron M., Alexis Reisin Miller, Benjamin Chacko, and Andrew S Robertson. 2020. “FDA Reported Use of Patient Experience Data in 2018 Drug Approvals.” Therapeutic Innovation & Regulatory Science 54 (3): 709–716. https://doi.org/10.1007/s43441-019-00106-1.

Harvard

Kieffer, C. M. et al. (2020) ‘FDA Reported Use of Patient Experience Data in 2018 Drug Approvals’, Therapeutic Innovation & Regulatory Science, 54(3), pp. 709–716. doi:10.1007/s43441-019-00106-1.

IEEE

C. M. Kieffer, A. R. Miller, B. Chacko, and A. S. Robertson, “FDA Reported Use of Patient Experience Data in 2018 Drug Approvals,” Therapeutic Innovation & Regulatory Science, vol. 54, no. 3, pp. 709–716, 2020, doi: 10.1007/s43441-019-00106-1.

BibTeX

@article{kieffer2020reported,
  title     = {{FDA Reported Use of Patient Experience Data in 2018 Drug Approvals}},
  author    = {Kieffer, Cameron M. and Miller, Alexis Reisin and Chacko, Benjamin and Robertson, Andrew S},
  journal   = {Therapeutic Innovation \& Regulatory Science},
  year      = {2020},
  volume    = {54},
  number    = {3},
  pages     = {709--716},
  doi       = {10.1007/s43441-019-00106-1},
  url       = {https://doi.org/10.1007/s43441-019-00106-1}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202044
202111
202288
202366
202499
202522
202644

Its field-weighted citation impact is 4.35: it has been cited 4.35 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare

  • patient experience data
  • FDA drug approval
  • 21st Century Cures Act
  • patient-reported outcomes
  • new chemical entities
  • regulatory decision-making

Work with this paper

Most-cited papers in Nursing

All highly cited Nursing papers

Questions about this paper

How do I cite this paper in APA style?

Kieffer, C. M., Miller, A. R., Chacko, B., & Robertson, A. S. (2020). FDA Reported Use of Patient Experience Data in 2018 Drug Approvals. Therapeutic Innovation & Regulatory Science, 54(3), 709–716. https://doi.org/10.1007/s43441-019-00106-1

How many times has this paper been cited?

34 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Therapeutic Innovation & Regulatory Science: sign in and open the PDF from this page.

Who wrote this paper?

Cameron M. Kieffer, Alexis Reisin Miller, Benjamin Chacko, Andrew S Robertson.

What is the DOI of this paper?

10.1007/s43441-019-00106-1, permanently at https://doi.org/10.1007/s43441-019-00106-1. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.